Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 11Carcinoma, Hepatocellular 10Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 6Melanoma 4Endometrial Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Adenoid Cystic 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Clear Cell Carcinoma 1Non-squamous Non-small-cell Lung Cancer 1NSCLC 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

pembrolizumab 5Cisplatin 5Platinum 4Pemetrexed 41,2-diaminocyclohexaneplatinum II citrate 4Nivolumab 3Cyclophosphamide 3fludarabine 2atezolizumab 2Ipilimumab 2Carboplatin 2tremelimumab 1sargramostim 1methoxyamine 1lenvatinib 1cediranib 1anetumab ravtansine 1UV1 vaccine 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Interleukin-2 1Imprint II 1Immunotherapy, Adoptive 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Bevacizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mesothelioma, Malignant × lenvatinib × Clear all
NCT04287829 2024-11-05

PEMMELA

The Netherlands Cancer Institute

Phase 2 Active not recruiting
58 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡